



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Feedback control of AHR signalling regulates intestinal immunity

Citation for published version:

Schiering, C, Wincent, E, Metidji, A, Iseppon, A, Li, Y, Potocnik, A, Omenetti, S, Henderson, CJ, Wolf, CR, Nebert, DW & Stockinger, B 2017, 'Feedback control of AHR signalling regulates intestinal immunity', *Nature*, vol. 542, pp. 242-245. <https://doi.org/10.1038/nature21080>

Digital Object Identifier (DOI):

[10.1038/nature21080](https://doi.org/10.1038/nature21080)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Nature

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Feedback Control of AHR Signalling Regulates Intestinal Immunity

Chris Schiering¹, Emma Wincent[§], Amina Metidji¹, Andrea Iseppon¹, Ying Li¹,
Alexandre J. Potocnik², Sara Omenetti, Colin J. Henderson^{*}, C. Roland Wolf^{*},
Daniel W. Nebert[¶] and Brigitta Stockinger¹

¹The Francis Crick Institute, Mill Hill Laboratory, London UK

²Institute of Immunology and Infection Research, The University of Edinburgh,
UK

[§] Swedish Toxicology Sciences Research Center, Södertälje, Sweden

^{*} Dundee University School of Medicine, Division of Cancer Research, Dundee,
UK

[¶] University of Cincinnati, Department of Environmental Health, Cincinnati, USA

<http://www.nature.com/nature/journal/v542/n7640/full/nature21080.html>

doi:10.1038/nature21080

The aryl hydrocarbon receptor (AHR), a ligand dependent transcription factor, plays an important role in the recognition of xenobiotics as well as natural compounds such as tryptophan metabolites, dietary components and microbiota-derived factors¹⁻⁴ and is important for maintenance of homeostasis at mucosal surfaces. AHR activation induces cytochrome P450 (CYP1) enzymes, which function to oxygenate AHR ligands, leading to their metabolic clearance and detoxification⁵. Thus, CYP1 enzymes appear to play an important feedback role that curtails the duration of AHR signalling⁶, but it remains elusive whether they also regulate AHR ligand availability and signal intensity *in vivo*, processes that are of physiological importance for the intestinal immune system.

Here we show that dysregulated expression of *Cyp1a1* depletes the reservoir of natural AHR ligands, thereby generating a quasi AHR-deficient state. Using a *Cyp1a1* reporter strain we identified intestinal epithelial cells (IECs) as first line responders to dietary AHR ligands. Constitutive expression of *Cyp1a1* throughout the body or restricted specifically to IECs resulted in loss of AHR-dependent type 3 innate lymphoid cells (ILC3) and T helper 17 (Th17) cells and increased susceptibility to enteric infection. These profound effects of excessive AHR ligand degradation on intestinal immune system function could be counter-balanced by increasing the intake of AHR ligands in the diet. Thus, our results demonstrate that IECs serve as gatekeepers for the supply of AHR ligands to the host and emphasise the importance of feedback control in modulating AHR pathway activation.

It is increasingly understood that AHR signalling needs to be tightly controlled as prolonged activation either by ligands that resist metabolic clearance or in mice with constitutively active AHR has deleterious effects⁷⁻¹⁰. Enzymes of the CYP1A and CYP1B sub-families (CYP1) appear to be central to the control of AHR signalling due to their capacity for metabolising ligands and thereby terminating AHR activation.

We hypothesized that excessive CYP1A1-mediated metabolic clearance of natural AHR ligands would cause a strong phenotype in the intestinal immune system, given that several immune cell types are dependent on ligand-mediated AHR signalling for their survival. In order to investigate this, we generated a mouse model with constitutive *Cyp1a1* expression due to its placement under control of the ubiquitously active *Rosa26* promoter (*R26^{Cyp1a1}*) (Extended Data Fig.1). As proof of principle we investigated the effect of constitutive *Cyp1a1* expression on Th17 cells, which are known to express AHR and produce IL-22 in an AHR-dependent manner¹¹. Th17 cells generated from *R26^{Cyp1a1}* mice had significantly increased CYP1A1 enzymatic activity compared with wild-type B6 (WT) or *Ahr*-deficient Th17 cells (Fig.1a). We then cultured CD4⁺ T cells from WT, *Ahr*-deficient or *R26^{Cyp1a1}* mice under Th17 cell conditions in the presence of the endogenous, tryptophan-derived AHR ligand 6-formylindolo[3,2-*b*]carbazole (FICZ) and measured residual cellular FICZ levels following metabolic clearance over 48h of culture. FICZ levels did not decay in cultures of *Ahr*-deficient Th17 cells in line with the absence of CYP1A1 induction, but cultures of *R26^{Cyp1a1}* Th17 cells showed accelerated clearance of FICZ compared with those from WT Th17 cells (Fig.1b). Furthermore, Th17 cells generated from *R26^{Cyp1a1}* mice showed a pronounced deficiency in IL-22 production to baseline AHR ligands present in

culture medium¹² and to low concentrations of FICZ, whereas higher FICZ concentrations overcame this effect (Fig.1c and Extended Data Fig.2). *Ahr*-deficient Th17 cells did not produce IL-22 under any condition (Fig.1c). Thus, constitutive CYP1A1 activity caused a decrease in AHR ligands that compromised induction of IL-22.

Ahr deficiency in haematopoietic cells results in the disappearance of several cell types in the intestinal immune system, such as intraepithelial lymphocytes¹³ and innate lymphoid cells (ILC3)¹⁴⁻¹⁶. *R26^{Cyp1a1}* mice exhibited enhanced intestinal CYP1A1 enzyme activity (Extended Data Fig.3a) and loss of ILC3 in colon and small intestine similar to *Ahr*-deficient mice (Fig.1d,e and Extended Data Fig.3b), suggesting that rapid metabolic clearance of natural AHR ligands mimics an *Ahr*-deficient state under homeostatic conditions. In addition, *R26^{Cyp1a1}* mice displayed similar developmental abnormalities to *Ahr*-deficient mice, such as decreased liver weight indicative of patent ductus venosus¹⁷ (Extended Data Fig.8).

We next investigated the response of *R26^{Cyp1a1}* mice to infection with the intestinal pathogen *Citrobacter rodentium*. This infection causes severe pathology in *Ahr*-deficient¹⁴⁻¹⁶, compared with WT mice. *R26^{Cyp1a1}* mice similarly had increased colon and cecal pathology scores, albeit not quite as extensive as those seen in *Ahr*-deficient mice (Fig.2a,b). While all WT mice survived the infection, *Ahr*-deficient mice reached endpoint at which they had to be culled by day 9 after infection and *R26^{Cyp1a1}* mice survived only a few days longer (Fig.2c). *C. rodentium* penetrated deeply into the base of the crypts in *Ahr*-deficient and *R26^{Cyp1a1}* mice, whereas it mainly attached to the luminal surface of the epithelium in WT mice (Fig.2d). We observed a significantly higher bacterial burden in the colon of *Ahr*-deficient and *R26^{Cyp1a1}* mice and failure to clear the infection resulted in dissemination of bacteria to liver and spleen (Fig.2e). IL-22 is essential

in the defence against *C. rodentium*¹⁸ and the extreme susceptibility of *Ahr*-deficient mice can be attributed to their lack of ILC3 as well as failure to mount a T cell IL-22 response. This deficiency in IL-22 as well as Th17 cells and ILC3 was mirrored in *R26^{Cyp1a1}* mice (Fig.2f, g). Administration of recombinant IL-22–Fc fusion protein significantly reduced bacterial burden and crypt invasion and prolonged survival of *R26^{Cyp1a1}* mice (Extended Data Fig.4).

Thus, constitutive *Cyp1a1* expression severely impairs the intestinal immune response against an enteric pathogen.

If CYP1A1-mediated clearance of natural ligands produces a quasi *Ahr*-deficient state, the absence of such metabolic clearance should increase ligand availability. To test this, we took advantage of a mouse strain lacking the three AHR controlled CYP enzymes CYP1A1, CYP1A2 and CYP1B1, termed *Cyp1* knockout¹⁹. Th17 cells from *Cyp1* knockout mice failed to metabolise the ligand FICZ and showed increased *Cyp1a1* expression as well as substantially enhanced IL-22 production in the absence of added AhR ligands as well as reduced histopathology scores and bacterial burdens upon infection (Extended Data Fig.5). Increased ligand availability in *Cyp1*-deficient mice could be visualized in a *Cyp1a1* fate-reporter mouse that reports AHR activity via induction of an eYFP reporter activated due to targeted insertion of Cre recombinase in the murine *Cyp1a1* locus²⁰. Although *Cyp1*-deficient mice fail to produce this enzyme, they still report AHR stimulation by induction of Cre mediated eYFP activation. In the intestine of WT *Cyp1a1* reporter mice eYFP expression is scarce, reflecting the transient nature of AHR signalling that limits Cre induction (Fig.3a left). However, in *Cyp1*-deficient mice there was an enhanced eYFP signal in the intestinal epithelium (Fig.3a left). Supplementation of the diet with indole-3-carbinol (I3C), a tryptophan-derived phytochemical that is converted to high

affinity AHR ligands by exposure to stomach acid²¹, further enhanced the eYFP signal in *Cyp1*-deficient mice (Fig.3a right). Importantly, *Cyp1a1* was predominantly expressed in intestinal epithelial cells (Fig.3b).

It has been shown previously that IEC specific deletion of the AHR partner ARNT causes systemic upregulation of *Cyp1a1*²². Thus, we next tested the effect of epithelial-specific constitutive *Cyp1a1* expression using *Villin-cre-R26^{LSL-Cyp1a1}* mice (termed IEC^{*Cyp1a1*}). *Cyp1a1* expression (read out as rat Thy1 expression) was detectable only in CD45- IEC in these mice (Extended Data Fig.1b). Surprisingly, however, IEC^{*Cyp1a1*} mice had drastically reduced numbers of ILC3 similar to *Ahr*-deficient mice and mice with constitutive *Cyp1a1* expression throughout the body (Fig. 3c).

In contrast, mice in which constitutive *Cyp1a1* expression was restricted to adaptive immune cells via *Rag1-Cre* (*Rag1^{Cyp1a1}*) had normal numbers of ILC3 under steady state conditions (Fig.3c and Extended Data Fig.1b).

This suggests that constitutive CYP1A1 activity in IECs, but not in adaptive immune cells, restricts the availability of AHR ligands to cells in the intestinal lamina propria, resulting in loss of AHR ligand-dependent ILC3.

Upon infection with *C. rodentium* IEC^{*Cyp1a1*} mice rapidly succumbed (Fig. 3d) with increased bacterial crypt invasion (Fig. 3e) and intestinal pathology (Fig. 3f).

C. rodentium disseminated into liver and spleen of IEC^{*Cyp1a1*} mice (Fig.3g) and the reduction of ILC3 and Th17 cells collectively affected the amount of IL-22 that was detectable in colon tissue (Fig.3h). In contrast, *C. rodentium* infected *Rag1^{Cyp1a1}* showed similar survival to WT mice over 14 days after infection and no significant differences in bacterial load, pathology score or dissemination of bacteria were observed (Extended Data Fig.6). While ILC3 were not affected, Th17 cells and their IL-22 production were strongly reduced (Extended Data Fig.6d). Thus, enhanced AHR ligand degradation in T cells compromises T cell

derived IL-22 responses, but spares ILC3. In contrast, enhanced AHR ligand degradation in IEC deprives ILC3 as well as T cells of AHR stimulation, thereby causing a more severe deficiency in immune defence against *C. rodentium*.

Next we investigated whether lack of AHR ligand metabolism by non-haematopoietic cells affects the immune response to *C. rodentium* infection. To this end we generated bone marrow chimeras by transferring WT donor bone marrow into irradiated WT (WT → WT) or *Cyp1*-deficient (WT → *Cyp1*^{-/-}) recipients, followed by infection with *C. rodentium*. WT → *Cyp1*^{-/-} chimeras showed significantly reduced pathology scores (Fig.3i) as well as bacterial loads (Fig.3j) as compared to WT recipients (WT→WT). Furthermore, *Cyp1*^{-/-} recipients had increased numbers of WT donor-derived ILC3 and Th17 cells and markedly higher IL-22 levels (Fig3k). Thus, absence of CYP1-mediated AhR ligand metabolism in non-haematopoietic cells, such as IEC, results in increased ligand availability to intestinal immune cells and promotes resistance to enteric infection. Although bone marrow chimeras cannot unequivocally identify IEC as the responsible cell type, the data are consistent with a crucial role for IEC as gatekeepers for the availability of AhR ligands in the intestinal immune system.

To further substantiate the central role of CYP1A1 in controlling ligand availability, we investigated whether increasing AHR ligands by exogenous application via the diet might mitigate the loss of AHR signalling in *R26*^{*Cyp1a1*} mice. This possibility seemed plausible on the basis of the *in vitro* data with Th17 cells, which indicated that increasing AHR ligand dose could saturate CYP1A1-mediated metabolic activity (Fig.1c).

We therefore introduced I3C to the diet of *R26^{Cyp1a1}* mice for 4 weeks prior to subjecting them to infection with *C. rodentium*. *R26^{Cyp1a1}* mice that were fed on control diet all succumbed to infection by day 12 and failed to clear the infection, whereas all mice on the I3C supplemented diet survived and had cleared the infection by day 14 (Fig.4a,b). Penetration of *C.rodentium* to the crypts was abrogated (Fig.4c) and the pathology scores of mice on I3C diet were drastically reduced (Fig.4d,e). Analysis of IL-22 levels showed recovery of IL-22 producers in *R26^{Cyp1a1}* mice on I3C diet (Fig.4f,g), whereas blockade of IL-22 during I3C diet exposure abrogated the protective effect (Fig.4h). The beneficial effects of I3C are most likely due to the strong inhibition of CYP1A1 activity by its acid-condensation products DIM and ICZ (Fig. 4i). In addition, DIM and ICZ were previously shown to be AHR ligands²³, suggesting that reduced pathology observed after I3C supplementation may result from increased availability of endogenous ligands due to CYP1A1 inhibition as well as increased levels of exogenous ligands such as DIM and ICZ. ICZ like FICZ, but unlike DIM is also efficiently metabolised by CYP1A1 (Extended Data Fig.7).

Thus, the excessive clearance of natural ligands, which produces a quasi *Ahr*-deficient state in *R26^{Cyp1a1}* mice can be ameliorated by the supply of dietary AHR ligands, allowing sufficient AHR signalling to restore IL-22 production by Th17 cells and successful eradication of *C. rodentium*.

Discussion

The AHR pathway is of crucial importance in the intestinal immune system as shown by the phenotypes of *Ahr*-deficient mice and genome-wide association studies that have identified *AHR* as a susceptibility locus in inflammatory bowel disease²⁴. While in recent years the focus has been on AHR itself or on identification of ligands^{2,4,25}, we show here that feedback regulation of the AHR pathway by CYP1 enzymes is a critical checkpoint that controls ligand availability and thereby activation of the AHR pathway.

Dysregulated CYP1A1 activity in IECs profoundly affects the availability of AHR ligands in the body. Constitutive CYP1A1 activity in IEC resulted in a phenotype closely resembling that of *Ahr*-deficient mice, with the decay of intestinal immune cells such as ILC3 that depend on AHR signals for survival and impairment of the adaptive IL-22 response upon infection with intestinal pathogens. Conversely, lack of CYP1A1-mediated metabolism confined to IEC had the opposite effect, increasing protection against intestinal infection.

Thus, IEC constitute an important checkpoint for AHR ligand availability.

It has been shown previously in an *in vitro* setting that inhibition of CYP1A1 results in a boost to AHR pathway activation due to increased availability of AHR ligand FICZ²⁶. Here we demonstrate that genetic deletion of CYP1 enzymes, restricted to nonhaematopoietic cells, delays ligand metabolism, resulting in increased AHR signals *in vivo*. Sources of AHR ligands are abundant and include dietary compounds²¹, microbial virulence factors⁴ as well as AHR ligands derived via microbiota or host cell-mediated tryptophan metabolism². Given that environmental factors such as oxidative stress, chemical pollutants and dietary factors have been shown to modulate CYP1 enzyme activity²⁶, any interference with CYP1-mediated AHR ligand degradation has potential consequences for AHR pathway activation and intestinal homeostasis.

In this context, our finding that the intestinal pathology resulting from constitutive CYP1A1 activity upon infection with *C. rodentium* could be counter-balanced by increasing the intake of AHR ligands in the diet suggests that dysregulated CYP1A1 activity is potentially amenable to therapeutic manipulation via dietary supplementation.

Online Material and Methods

Mice:

For the generation of a constitutively active as well as an inducible *Cyp1a1* allele the coding sequence (CDS) of *Cyp1a1* was linked to the CDS of rat *Thy1* using a 2A sequence. In order to stabilize the transcriptional activity of the inserted genes, a woodchuck hepatitis virus-derived regulatory element in conjunction with a bovine growth hormone polyadenylation site was inserted 3' of the CDSs. This module was inserted downstream of a cassette containing an FRT-flanked neomycin-resistance gene and loxP-flanked transcriptional stop elements. The targeting vector did not contain any artificial promoter for the expression of both *Cyp1a1* and rat *Thy1* to avoid toxicity caused by *Cyp1a1* overexpression (details of the gene targeting and *Rosa26*-targeting strategy, Extended Data Figure 1). The targeting vector was generated by Biocytogen and used to establish *R26^{Cyp1a1}-neoR* mice by homologous recombination in BCGEN B61-6 (C57BL/6) embryonic stem cells. *R26^{Cyp1a1}-neoR* mice were generated after successful germ line transmission and backcrossed to C57BL/6J. This strain was further bred with mice expressing the Cre recombinase under the control of the mouse protamine (Prm1) promoter to obtain constitutive *Cyp1a1* expression in all cell-types (referred to as *R26^{Cyp1a1}* mice) or with ACTB:FLPe mice to obtain mice with a conditional floxed *Cyp1a1* allele (referred to as *R26^{LSL-Cyp1a1}*). These were crossed with Villin-cre mice to generate the IEC^{*Cyp1a1*} strain (constitutive *Cyp1a1* expression specific to intestinal epithelial cells) and Rag1-cre mice to generate the *Rag1^{Cyp1a1}* strain (constitutive *Cyp1a1* expression specific to T and B cells).

To generate the *Cyp1a1* reporter strain *Cyp1a1^{Cre}* mice²⁰ (with targeted insertion of Cre recombinase in the murine *Cyp1a1* locus) were crossed with *R26R^{eYFP}*

mice²⁷, expressing eYFP from the ubiquitous *Rosa26* promoter downstream of a cassette containing a loxP-flanked transcriptional stop element. This strain was further bred with *Cyp1^{-/-}* mice¹⁹ to obtain *Cyp1^{-/-} Cyp1a1* reporter mice. All mice used in this study were either generated in C57BL/6 ES cells or backcrossed to C57BL/6 mice for at least 10 generations. All mice were bred in the Francis Crick Institute animal facility under specified pathogen-free conditions. All animal procedures were conducted under a Project Licence granted by the UK Home Office. Mice were age and sex-matched and more than 6 weeks old when first used. Both female and male mice were used in experiments.

***In vitro* T cell differentiation**

CD4⁺ T cells were isolated using EasySep mouse CD4⁺ T cell isolation kit (Stemcell Technologies) with the addition of biotinylated anti-CD25 antibody (BioLegend). Cells were cultured in Iscove's modified Dulbecco medium (IMDM, Sigma) supplemented with 2mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.05mM β-mercaptoethanol and 5% fetal calf serum (biosera). CD4⁺ T cells were differentiated in 48 well plates coated with 1 µg/ml anti-CD3 (clone 145-2C11, eBioscience) and 10 µg/ml soluble anti-CD28 (clone 37.51, BioLegend) in the presence of 2ng/ml TGF-β1, 20ng/ml IL-6, 10ng/ml IL-1β (all R&D Systems) and 10µg anti-IFN-γ (BioXCell). In some cultures 6-formylindolo[3,2-*b*]carbazole (FICZ, EnzoLifeSciences) was added from the start of culture. IL-22 cytokine levels in culture supernatants were determined by ELISA (eBioscience).

Isolation of lamina propria cells and flow cytometry

Colon and small intestine were cut open longitudinally and incubated in wash buffer (IMDM 1%FCS, 5mM EDTA, 10mM HEPES, penicillin/streptomycin, and

2mM DTT) for 20min at 37°C with 200rpm shaking. Colon tissue was collected, cut into small pieces and incubated in digestion buffer (IMDM supplemented with 1% FCS, 10mM HEPES, penicillin/streptomycin, 50µg/ml DNase I (Roche)) containing 0.4mg/ml Liberase TL (Roche) and incubated for 30min at 37°C with 200rpm shaking. Small intestinal tissue was collected, cut into small pieces and incubated in digestion buffer (IMDM supplemented with 1% FCS, 10mM HEPES, penicillin/streptomycin, 50µg/ml DNase I (Roche)) containing 1mg/ml Collagenase VIII (Sigma) and incubated for 10min at 37°C with 200rpm shaking. Single cell suspensions from colon and small intestine were further subjected to 40% Percoll (Amersham) density gradient centrifugation to remove debris. For surface staining, cell suspensions the lamina propria were incubated with anti-CD16/CD32 (eBioscience) and fixable live/dead cell dye (ThermoFisher) followed by staining with antibodies against CD11b, CD3, TCRγδ, Gr1, CD11b, CD19, NKp46, CCR6, TCR-β (all BioLegend) and Thy1.2, CD45, CD4 (all BD Biosciences). For intracellular staining, single cell suspension were re-stimulated for 2hrs and 15min in the presence of 1ng/ml phorbol-12-myristate-13-acetate (PMA), 1 µg/ml ionomycin and 10 µg/ml Brefeldin A (all Sigma), washed and stained for surface markers as described above. Cell were then fixed in eBioscience Fix/Perm buffer or 4% formaldehyde (for preservation of eYFP fluorescence) for 30min on ice followed by permeabilization in eBioscience permeabilization buffer for 45min in the presence of antibodies against IL-17A, IL-22, T-bet (all ebioscience) and RORγt (BD Biosciences). Cells were acquired with a BD Fortessa X20 and analysis was performed with FlowJo v10 (Tree Star) software.

High performance liquid chromatography (HPLC) analysis of FICZ clearance and CYP1A1-mediated metabolism of DIM, ICZ and FICZ.

Cellular clearance: CD4⁺ T cells were isolated and cultured under Th17-cell-inducing conditions as described above and 5nM FICZ (EnzoLifeSciences) added at the start of culture. At various time-points cells were collected, washed in PBS and re-suspended in 200µl distilled water and stored at -20°C. Prior to HPLC analysis the cells were homogenized by sonication on ice (4 x 5 seconds) using a MSE Soniprep 150 equipped with an exponential probe (Measuring and Scientific Equipment). Extraction and chemical analysis of the homogenates, using an in-line solid-phase extraction column coupled to a reverse-phase C18 analytical column, was performed as previously described²⁶. FICZ quantity was determined according to a standard curve of FICZ and the results were normalized to total protein contents determined by Pierce Coomassie protein assay kit according to the manufacturer's instructions.

CYP1A1-mediated metabolism: Time-dependent metabolism of DIM, ICZ and FICZ was studied in the presence of human recombinant CYP1A1 (3.5nM) and the co-factor NADPH (1.0mM). Each compound (0.1µM) was incubated with CYP1A1 and NADPH in Tris-HCl (0.1M, pH 7.4) with EDTA (1mM) at 37°C. At various time-points samples were collected and acetonitrile was added to each sample at a final concentration of 20%, followed by vortexing (30 seconds) and centrifugation (10 minutes at 12x10⁶ rpm and 4°C). Chemical analysis of the supernatants was performed using the same HPLC equipment as for the cellular clearance measurements. Separation of respective compound was achieved using a reverse-phase C18-AR column (ACE, 4.6 × 150mm, 5µm particle size) with a mobile phase consisting of water (A) and acetonitrile (B), both containing 1.5mM formic acid. Initially, the solvent contained 30% B, with a linear increase to 100% B during a period of 20 min, at a flow rate of 0.8 mL/min. DIM, ICZ and FICZ

was detected using excitation/emission wavelengths of 230/460 (DIM and ICZ) or 390/525nm (FICZ). All compounds were quantified according to separate standard curves. To determine non-enzymatic degradation of each compound parallel incubations were performed where phosphate buffer was substituted for nadph.

Ethoxyresorufin-O-Deethylase (EROD) Assay

Intestinal tissue homogenates or CD4⁺ T cells cultured for 48 hours under Th17-cell-inducing conditions were washed in PBS followed by incubation with 2 μ M 7-ethoxyresorufin in sodium phosphate buffer (50 mM, pH 8.0) at 37 °C for 30 minutes. The reaction was terminated by adding fluorescamine (Sigma) dissolved in acetonitrile. Formation of resorufin (excitation/emission of 535/590nm) and fluorescamine (excitation/emission of 390/485nm) was quantified using a plate reader.

Inhibition of CYP1A1 activity by I3C, DIM and ICZ.

Effects on the ethoxyresorufin deethylase (EROD) activity of human recombinant CYP1A1 (2.5nM) was assayed by first pre-incubating the enzyme with the compound to be tested for 5 min in Tris-HCl (0.1M, pH 7.4) with EDTA (1mM) at 37°C followed by addition of ethoxyresorufin (0.1 μ M) and NADPH (0.4 mM). Formation of resorufin was quantified using a multiwell plate reader with the excitation/emission wavelengths of 535/590 nm) and activity of the enzyme was determined by the rate of resorufin formation. ICZ and FICZ were purchased from Syntastic AB (Stockholm, Sweden). DIM, I3C, 7-ethoxyresorufin, β -Nicotinamide adenine dinucleotide 2'-phosphate (NADPH, N7505) and human recombinant cytochrome P4501A1 with P450 reductase (C3735) was purchased from Sigma-Aldrich.

Immunofluorescence Microscopy

Tissues were fixed in 4% phosphate-buffered formaldehyde solution (Fisher Scientific) for 24 hours. Fixed tissue sections were de-paraffinised and antigen retrieval performed in 0.01M sodium citrate buffer. Slides were blocked with goat serum, stained with mouse anti-E-cadherin (BD, 610181) and rabbit anti-*C. rodentium* antiserum followed by staining with secondary antibodies (AF555-conjugated goat-anti-rabbit and AF488-conjugated goat-anti-mouse from ThermoFisher). Slides were further stained with DAPI (Sigma) and mounted in Fluoromount-G (SouthernBiotech) and visualized using a Leica Confocal SP5-Invert microscope. For staining of eYFP, tissue sections were fixed in 4% paraformaldehyde at 4°C for 16 hours followed by incubation in 30% sucrose for 24 hours. Tissues were embedded in O.C.T. compound (VWR) followed by cryosectioning. Slides were blocked with rabbit serum and stained with AF488-conjugated rabbit-anti-GFP (ThermoFisher, A21311) and AF647-conjugated mouse-anti-E-cadherin (BD, 560062) and visualized using a Leica Confocal SP5-Invert microscope. Image analysis was performed in ImageJ.

Infection with *Citrobacter rodentium*

For *C. rodentium* infection a single colony of strain DBS100 (ATCC 51459; American Type Culture Collection) was transferred to Luria–Bertani (LB) broth and grown to log phase followed by centrifugation and resuspension in PBS. Mice were orally gavaged with 200µl of PBS containing 2×10^9 *C. rodentium*. To determine bacterial load, intestinal tissue pieces or faecal pellets were weighed and homogenized in sterile PBS and serial dilutions were plated onto Brilliance *E. coli*/coliform Selective Agar (Fisher Scientific) or LB agar plates (liver and

spleen) for measurement of colony-forming units (CFU). For neutralization of IL-22, mice were injected intraperitoneally (i.p.) three times per week with 150µg/mouse per dose monoclonal anti-IL-22 (clone 8E11, Genentech) or mouse IgG1 isotype control (BioXCell/2BScientific). Where indicated, mice were injected i.p. three times per week with 125µg/ml per dose IL-22–Fc (PRO312045, Genentech) or mouse IgG2a isotype control (BioXCell/2BScientific).

Diet studies

For diet studies mice were fed purified diet AIN-93M (TestDiet-IPS) or AIN-93M supplemented with 200ppm indole-3-carbinol (Sigma). Mice were put on purified diets shortly after weaning for at least 4 weeks and maintained on the purified diets throughout the duration experiments.

Generation of bone marrow chimeric mice

Bone marrow was injected intravenously (2.5×10^6 cells per mouse) into recipient mice irradiated with two doses of 5Gy using a ^{137}Cs -source. Donor bone marrow and recipient mice were distinguished on the basis of congenic markers. Chimeric mice were used in experiments 6-8 weeks following reconstitution.

Colon explant cultures

Intestinal tissue pieces (0.5-1cm length) were cultured for 24 hours in complete IMDM medium. IL-22 cytokine levels in the supernatants were determined by ELISA (eBioscience) and concentrations were normalized to the weight of the explants.

Histological Assessment

Tissues from distal colon and caecum were fixed in 4% phosphate-buffered

formaldehyde solution (Fisher Scientific) for 24 hours, cut and stained with hematoxylin and eosin. Slides were blinded and scored (0-15) for parameters of inflammation and tissue damage as described in²⁸.

Statistical Analysis

For comparisons between two groups unpaired, two-tailed Student's *t*-test was used or when appropriate a two-way ANOVA with Dunnett's post-test. For the comparison of three groups a one-way ANOVA followed by Tukey multiple comparison test was performed. All statistical analysis was calculated in Prism (GraphPad 6).

Extended Data Figure Legends

Extended Data Figure 1: Generation of $R26^{Cyp1a1}$ allele.

a, The endogenous *Rosa26* locus, the gene targeting vector, the targeted *Rosa26* allele including the Neo resistance gene cassette ($R26^{Cyp1a1-neoR}$), the targeted allele ($R26^{LSL-Cyp1a1}$) after FLPe-mediated recombination and the ubiquitously expressed $R26^{Cyp1a1}$ are schematically depicted to scale. A minigene composed of the coding sequences of mouse *Cyp1a1* and rat *Thy1* connected by a 2A sequence followed by the woodchuck hepatitis virus derived regulatory element (WPRE) and a bovine growth hormone polyadenylation site (bGH pA). **b**, Expression of rat THY1 in indicated cell types in the colon of $R26^{Cyp1a1}$, IEC^{Cyp1a1} (Villin-Cre), $Rag1^{Cyp1a1}$ (Rag1-Cre) strains.

Extended Data Figure 2: Altered AHR ligand availability affects IL-22 production.

Flow cytometry analysis of IL-17A and IL-22 expression in *in vitro* differentiated Th17 cells from indicated genotypes (day 4) exposed to DMSO, 0.01nM FICZ or 1nM FICZ from the start of culture.

Extended Data Figure 3: Altered AHR ligand affects intestinal AHR-dependent ILC populations.

a, CYP1A1 enzyme activity, measured by EROD assay, in intestinal tissue homogenates of steady state mice. **b**, Flow cytometry analysis of NKp46 and ROR γ t expression in CD45⁺ lineage negative (TCR β ⁻CD3⁻TCR γ δ ⁻CD19⁻CD11b⁻Gr1⁻) Thy1⁺ live cells in the small intestine (upper panel) and phenotypic analysis of ROR γ t⁺NKp46⁻ innate lymphoid cells (lower panel).

Results are representative of three independent experiments (n=3).

Error bars, mean \pm s.e.m. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, as calculated by one-way ANOVA with Tukey post-test.

Extended Data Figure 4: IL-22-Fc improves resistance to *C. rodentium* infection in *R26^{Cyp1a1}* mice.

Mice of indicated genotypes were infected orally with $\sim 2 \times 10^9$ *C. rodentium* and killed 7 days after infection or monitored for survival. **a**, *C. rodentium* burdens in the colon and cecum. Bars are the median and each symbol represents an individual mouse. **b**, Colon sections stained for E-Cadherin (green), *C. rodentium* (red) and DAPI (blue). Scale bars represent 100 μ m. **c**, Survival plot.

Results are representative of three independent experiments.

NS = not significant, ** $P < 0.01$, *** $P < 0.001$, as calculated by one-way ANOVA with Tukey post-test.

Extended Data Figure 5: *Cyp1*-deficiency enhances AHR pathway activation.

a, CD4⁺ T cells from indicated genotypes were cultured under Th17-cell-inducing conditions and exposed to FICZ from the start of culture. Intracellular levels of FICZ were determined by HPLC and normalized to total protein content at the indicated time points. **b**, Frequencies of IL-22-producing cells after 4 days of culture under Th17-cell-inducing conditions in presence of indicated concentrations of FICZ. Results are representative of three independent experiments (n=3 per experiment, mean \pm s.e.m). ** $P < 0.01$, *** $P < 0.001$ as calculated by two-way ANOVA with Dunnett's post-test **a**, or one-way ANOVA with Tukey post-test **b**. ns = not significant. **c**, Flow cytometry analysis of *Cyp1a1* (eYFP) expression by Th17 cells differentiated from indicated genotypes.

Plots are gated on IL-17A⁺ cells and numbers indicate frequencies. **d**, Representative flow cytometry plots of IL-17A and IL-22 expression in *in vitro* differentiated Th17 cells from indicated genotypes (day 4) exposed to DMSO, 0.01nM FICZ or 1nM FICZ from the start of culture. **e**, Mice of indicated genotypes were infected orally with $\sim 2 \times 10^9$ *C. rodentium* and bacterial burdens measured in the faeces at various time points. **f**, Pathology scores of distal colon. Bars are the mean and each symbol represents an individual mouse.

Results are representative of at least two independent experiments (n=3).

Error bars, mean \pm s.e.m. $**P < 0.01$, as calculated by Student's t-test.

Extended Data Figure 6: Effects of *Rag1-Cre* mediated *Cyp11a1* expression on immunity to *C. rodentium*.

Mice of indicated genotypes were infected orally with $\sim 2 \times 10^9$ *C. rodentium* and killed 14 days after infection or monitored for survival. **a**, Survival plot. **b**, *C. rodentium* burdens in the colon, cecum, liver and spleen. Bars are the median and each symbol represents an individual mouse. **c**, Pathology scores of distal colon and cecum. Bars are the mean and each symbol represents an individual mouse. **d**, Absolute numbers of cytokine-producing TCR β^+ CD4⁺ T cells in the colon of *C. rodentium* infected mice.

Results are representative of two independent experiments.

NS = not significant, $**P < 0.01$, as calculated by Student's t-test.

Extended Data Figure 7: CYP11A1-mediated metabolism of DIM, ICZ and FICZ.

a-c, CYP1A1-mediated metabolism of **a**, DIM **b**, ICZ and **c**, FICZ was studied over time in the presence of human recombinant CYP1A1 (3.5nM) and the co-factor NADPH (1.0mM). At indicated timepoints, samples from respective incubations were extracted and analysed by means of HPLC. All chemicals were quantified according to separate standard curves. Left panels show relative amount of compound remaining at each given timepoint compared to parallel incubations without co-factor present. Right panels show HPLC chromatograms at 40 minutes enzyme-incubation, with and without co-factor present. All three compounds were detected based on their fluorescence properties (fluorescence units, FLU).

Results are representative of two independent experiments with two biological replicates at each experiment (n=4).

Extended Data Figure 8: Effects of *Cyp1a1* overexpression on liver development.

a, Liver weight represented as percentage of body weight. **b**, Liver (left lobe) weight represented as percentage of body weight. Results are representative of two independent experiments. Bars are the mean and each symbol represents an individual mouse.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, as calculated by one-way ANOVA with Tukey post-test.

Figure legends

Figure 1: CYP1A1 controls AHR ligand availability.

a, CYP1A1 enzyme activity, measured by EROD assay, in *in vitro* differentiated Th17 cells (day 2). **b**, CD4⁺ T cells from indicated genotypes were cultured under Th17-cell-inducing conditions and exposed to FICZ from the start of culture. Intracellular levels of FICZ were determined by HPLC and normalized to total protein content at indicated time points. **c**, IL-22 protein quantified by ELISA from culture supernatants of *in vitro* differentiated Th17 cells (day 4). **d,e**, Absolute numbers of the indicated innate lymphoid cell subsets in the small intestine or colon. Results are representative of three independent experiments ($n=3$ per experiment). Error bars, mean \pm s.e.m. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, as calculated by one-way ANOVA with Tukey post-test **a**, **c**, **d** and **e** or two-way ANOVA with Dunnett's post-test in **b**. ns = not significant.

Figure 2: Depletion of natural AHR ligands leads to impaired immunity to *C. rodentium*.

Mice of indicated genotypes were infected orally with $\sim 2 \times 10^9$ *C. rodentium* and killed 7 days after infection or monitored for survival. **a**, Representative photomicrographs of hematoxylin and eosin (H&E) stained colon sections of *C. rodentium* infected mice. Scale bars represent 200 μ m. **b**, Pathology scores of distal colon and cecum. Bars are the mean and each symbol represents an individual mouse. **c**, Survival plot. **d**, Colon sections stained for E-Cadherin (green), *C. rodentium* (red) and DAPI (blue). Scale bars represent 100 μ m. **e**, *C. rodentium* burdens in the colon, liver and spleen. Bars are the median and each symbol represents an individual mouse. **f**, Absolute numbers of colonic ROR γ t⁺ ILC3 and IL-17A-producing TCR β ⁺CD4⁺ T cells (mean \pm s.e.m.) **g**, IL-22 protein quantified by ELISA from supernatants of distal colon organ explant cultures

(mean \pm s.e.m.). Data represent pooled results of at least two independent experiments. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, as calculated by one-way ANOVA with Tukey post-test.

Figure 3: IECs serve as gatekeeper for the supply of AHR ligands to the host.

a, Flow cytometry analysis of Cyp1a1 (eYFP) expression gated on live cells in the colon of mice fed control diet or diet supplemented with indole-3-carbinol (I3C) for two weeks (left panel) and colon sections stained for E-Cadherin (red), Cyp1a1 (eYFP) (green) and DAPI (blue) Scale bars represent 100 μ m (right panel). **b**, Histograms showing Cyp1a1 (eYFP) expression in the colon of WT Cyp1a1 reporter (WT) and *Cyp1^{-/-}* Cyp1a1 reporter (*Cyp1^{-/-}*) mice treated for two weeks with control or I3C diet. **c**, Absolute numbers of ROR γ ⁺ ILC3 in small intestine and colon of untreated mice of indicated genotypes. **d**, Survival plot of mice infected with $\sim 2 \times 10^9$ *C. rodentium*. **e**, Colon sections stained for E-Cadherin (green), *C. rodentium* (red) and DAPI (blue) of infected mice (day 7). Scale bars represent 100 μ m. **f**, Representative photomicrographs of (H&E) stained colon sections of *C. rodentium* infected mice (day 7). Scale bars represent 100 μ m. **g**, *C. rodentium* burdens in the colon, liver and spleen. Bars are the median and each symbol represents an individual mouse. **h**, Absolute numbers of colonic ROR γ ⁺ ILC3 and Th17 cells and IL-22 protein quantified from supernatants of distal colon organ explant cultures (mean \pm s.e.m.). **i**, Pathology scores (day 6) of distal colon and cecum in bone marrow chimeras of wildtype (WT \rightarrow WT) or Cyp1 deficient (WT \rightarrow *Cyp1^{-/-}*) recipients. Bars are the mean and each symbol represents an individual mouse. **j**, *C. rodentium* burdens in the colon. Bars are the median and each symbol represents an individual mouse. **k**, Absolute numbers of WT donor-derived colonic ROR γ ⁺ ILC3 and Th17 cells and IL-22 protein in distal

colon organ explant cultures (mean \pm s.e.m.) Results are representative of three independent experiments. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ as calculated by Student's t -test or one-way ANOVA with Tukey post-test. ns = not significant.

Figure 4: Dietary AHR ligands restore immunity to *C. rodentium*.

R26^{Cyp1a1} mice fed purified diet (Control diet) or purified diet supplemented with indole-3-carbinol (I3C diet) were infected orally with $\sim 2 \times 10^9$ *C. rodentium* and monitored for survival. **a**, Survival plot. **b**, *C. rodentium* burdens in the faeces at indicated time points. **c**, Colon sections of *C. rodentium* infected mice stained for E-Cadherin (green), *C. rodentium* (red) and DAPI (blue). Scale bars represent 100 μ m. **d**, Representative photomicrographs of H&E stained colon sections. Scale bars represent 100 μ m. **e**, Pathology scores of distal colon and cecum. Bars are the mean and each symbol represents an individual mouse. **f**, Flow cytometry analysis of IL-17A and IL-22 expression in TCR β^+ CD4 $^+$ T cells from the colon of *C. rodentium* infected mice. **g**, Absolute numbers of cytokine-producing TCR β^+ CD4 $^+$ T cells in the colon *C. rodentium* infected mice. **h**, Survival plot of *R26^{Cyp1a1}* mice fed I3C diet and treated with anti-IL-22 blocking antibody or isotype control. **i**, Concentration-dependent inhibition of human recombinant CYP1A1 enzyme activity by I3C, di-indolylmethane (DIM) and 6-formylindolo[3,2-*b*] (FICZ). Concentrations causing 50% inhibition (IC50) is stated in respective plot.

Results are representative of three independent experiments. Error bars, mean \pm s.e.m. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, as calculated by Student's t -test.

Acknowledgements:

This work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK, The UK Medical Research Council and the Wellcome Trust.

We would like to acknowledge the Biological Research Facility at the Francis Crick Institute for expert breeding and maintenance of our mouse strains, the Histopathology Facility for help with sections and staining and the Flow Cytometry Facility for cell sorting. We thank Prof. Gad Frankel (Imperial College) for the gift of antiserum to *Citrobacter rodentium* and Genentech, South San Francisco, California, USA for kindly providing anti-IL-22 and IL-22-Fc.

The study was supported by a Wellcome Advanced Investigator Grant (B.S.) and a Sir Henry Wellcome Fellowship and the Fondation Acteria (C.S.). C.H. and C.R.W. are funded by Cancer Research UK Programme Grant C4639/A10822. E.W. is funded by the Swedish Research Council FORMAS.

Author information:

The authors declare no competing financial interests.

Affiliations:

The Francis Crick Institute, London NW1 1AT, UK

Chris Schiering, Amina Metidji, Andrea Iseppon, Ying Li, Sara Omenetti and Brigitta Stockinger

Swedish Toxicology Sciences Research Center, Södertälje, Sweden

Emma Wincent

Institute of Immunology and Infection Research, The University of Edinburgh, UK

Alexandre J. Potocnik

**Dundee University School of Medicine, Division of Cancer Research, Dundee,
UK**

Colin J.Henderson and C.Roland Wolf

**University of Cincinnati, Department of Environmental Health, Cincinnati,
USA**

Daniel W. Nebert

Contributions:


C.S. designed, performed and analysed most of the experiments with input from A.M., A.I. Y.L.S.O. E.W. performed the metabolic studies, A.P. assisted in designing the construct for Rosa26 Cyp1a1 mice, C.J.H. and C.R.W. provided Cyp1a1 reporter mice and D.W.N. provided Triple Cyp KO mice. B.S. conceived the project and wrote the manuscript together with C.S.


References:

- 1 Denison, M. S. & Nagy, S. R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. *Annual review of pharmacology and toxicology* **43**, 309-334, (2003).
- 2 Zelante, T. *et al.* Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity* **39**, 372-385, (2013).
- 3 McMillan, B. J. & Bradfield, C. A. The aryl hydrocarbon receptor sans xenobiotics: endogenous function in genetic model systems. *Mol Pharmacol* **72**, 487-498, (2007).
- 4 Moura-Alves, P. *et al.* AhR sensing of bacterial pigments regulates antibacterial defence. *Nature* **512**, 387-392, (2014).
- 5 Schmidt, J. V. & Bradfield, C. A. Ah receptor signaling pathways. *Annual review of cell and developmental biology* **12**, 55-89, (1996).
- 6 Chiaro, C. R., Patel, R. D., Marcus, C. B. & Perdew, G. H. Evidence for an aryl hydrocarbon receptor-mediated cytochrome p450 autoregulatory pathway. *Mol Pharmacol* **72**, 1369-1379, (2007).
- 7 Bock, K. W. & Kohle, C. Ah receptor: dioxin-mediated toxic responses as hints to deregulated physiologic functions. *Biochemical pharmacology* **72**, 393-404, (2006).
- 8 Kerkvliet, N. I. Recent advances in understanding the mechanisms of TCDD immunotoxicity. *Int Immunopharmacol* **2**, 277-291, (2002).
- 9 Mitchell, K. A. & Elferink, C. J. Timing is everything: consequences of transient and sustained AhR activity. *Biochemical pharmacology* **77**, 947-956, (2009).
- 10 Andersson, P. *et al.* A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. *Proc Natl Acad Sci U S A* **99**, 9990-9995, (2002).
- 11 Veldhoen, M. *et al.* The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. *Nature* **453**, 106-109, (2008).
- 12 Veldhoen, M., Hirota, K., Christensen, J., O'Garra, A. & Stockinger, B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. *J Exp Med* **206**, 43-49, (2009).
- 13 Li, Y. *et al.* Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. *Cell* **147**, 629-640, (2011).
- 14 Kiss, E. A. *et al.* Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. *Science* **334**, 1561-1565, (2011).
- 15 Lee, J. S. *et al.* AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. *Nat Immunol* **13**, 144-151, (2012).
- 16 Qiu, J. *et al.* The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. *Immunity* **36**, 92-104, (2012).
- 17 Lahvis, G. P. *et al.* The aryl hydrocarbon receptor is required for developmental closure of the ductus venosus in the neonatal mouse. *Mol Pharmacol* **67**, 714-720, (2005).
- 18 Zheng, Y. *et al.* Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. *Nat Med* **14**, 282-289, (2008).

- 19 Dragin, N. *et al.* Phenotype of the Cyp1a1/1a2/1b1^{-/-} triple-knockout mouse. *Mol Pharmacol* **73**, 1844-1856, (2008).
- 20 Henderson, C. J. *et al.* Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability. *The Biochemical journal* **465**, 479-488, (2015).
- 21 Bjeldanes, L. F., Kim, J. Y., Grose, K. R., Bartholomew, J. C. & Bradfield, C. A. Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Proc Natl Acad Sci U S A* **88**, 9543-9547, (1991).
- 22 Ito, S., Chen, C., Satoh, J., Yim, S. & Gonzalez, F. J. Dietary phytochemicals regulate whole-body CYP1A1 expression through an arylhydrocarbon receptor nuclear translocator-dependent system in gut. *J Clin Invest* **117**, 1940-1950, (2007).
- 23 Nguyen, L. P. & Bradfield, C. A. The search for endogenous activators of the aryl hydrocarbon receptor. *Chem Res Toxicol* **21**, 102-116, (2008).
- 24 Liu, J. Z. *et al.* Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet* **47**, 979-986, (2015).
- 25 Soshilov, A. A. & Denison, M. S. Ligand promiscuity of aryl hydrocarbon receptor agonists and antagonists revealed by site-directed mutagenesis. *Molecular and cellular biology* **34**, 1707-1719, (2014).
- 26 Wincent, E. *et al.* Inhibition of cytochrome P4501-dependent clearance of the endogenous agonist FICZ as a mechanism for activation of the aryl hydrocarbon receptor. *Proceedings of the National Academy of Sciences of the United States of America* **109**, 4479-4484, (2012).
- 27 Srinivas, S. *et al.* Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. *BMC Dev Biol* **1**, 4, (2001).
- 28 Song-Zhao, G. X. *et al.* Nlrp3 activation in the intestinal epithelium protects against a mucosal pathogen. *Mucosal Immunol* **7**, 763-774, (2014).

Fig 1










Fig 3




Extended Data Figure 1


a




b




Extended Data Figure 2




Extended Data Figure 3



Extended Data Figure 4




Extended Data Figure 5




Extended Data Figure 6


a




b




C



d



Extended Data Figure 7



Extended Data Figure 8

